Analysts expect Neos Therapeutics, Inc. (NASDAQ:NEOS) to post earnings of ($0.60) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Neos Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.67). Neos Therapeutics reported earnings per share of ($1.14) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.4%. The business is expected to report its next earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Neos Therapeutics will report full-year earnings of ($2.89) per share for the current fiscal year, with EPS estimates ranging from ($2.99) to ($2.73). For the next fiscal year, analysts expect that the business will report earnings of ($1.57) per share, with EPS estimates ranging from ($1.90) to ($1.34). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Neos Therapeutics.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.22. Neos Therapeutics had a negative return on equity of 580.51% and a negative net margin of 339.52%. The company had revenue of $6.70 million during the quarter.
A number of brokerages recently commented on NEOS. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 price target on shares of Neos Therapeutics in a research note on Tuesday, September 26th. Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 8th. ValuEngine
raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Zacks Investment Research
raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Wednesday, October 18th. Finally, Wells Fargo & Company set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.00.
Several hedge funds and other institutional investors have recently modified their holdings of the company. TIAA CREF Investment Management LLC raised its holdings in shares of Neos Therapeutics by 4.9% in the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock worth $342,000 after buying an additional 2,168 shares during the period. Rhumbline Advisers raised its holdings in shares of Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after buying an additional 2,441 shares during the period. California State Teachers Retirement System raised its holdings in shares of Neos Therapeutics by 14.1% in the third quarter. California State Teachers Retirement System now owns 38,915 shares of the company’s stock worth $356,000 after buying an additional 4,800 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Neos Therapeutics by 13.0% in the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock worth $396,000 after buying an additional 6,223 shares during the period. Finally, UBS Group AG raised its holdings in shares of Neos Therapeutics by 6.1% in the first quarter. UBS Group AG now owns 108,714 shares of the company’s stock worth $783,000 after buying an additional 6,276 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.
Shares of Neos Therapeutics (NASDAQ:NEOS) traded down $0.33 during trading on Friday, reaching $10.10. The company had a trading volume of 729,800 shares, compared to its average volume of 555,959. Neos Therapeutics has a 52 week low of $4.85 and a 52 week high of $13.15. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.04 and a quick ratio of 2.84.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/23/0-60-eps-expected-for-neos-therapeutics-inc-neos-this-quarter.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.